Reported 1 day ago
UnitedHealth Group is set to report second-quarter results, having lost nearly 45% of its stock value since the beginning of the year amid legal and regulatory investigations. Despite these challenges, analysts remain positive, with 12 out of 15 recommending it as a 'buy.' The company is expected to report a revenue of $111.88 billion, although adjusted earnings per share are anticipated to decline significantly. Recent reports reveal that a surge in Medicare Advantage claims has contributed to revenue struggles and a reduced full-year outlook.
Source: YAHOO